patent.fyi
Applications  /  US 2026/0355225
United States Patent Application Publication

US 2026/0355225 A1

Published
Nov 12, 2026
Filed
Dec 4, 2023
Earliest date on the face
Dec 5, 2022
Classification
A61K 31/7004
First published here
Nov 19, 2026

Generated automatically. Not reviewed by a person. Not legal advice or an opinion.

Section 1 · machine-generated

What if?

Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.

1.1Chain initiation by a xyloside

What ifWhat if a β-D-xyloside with an aromatic group served as the chain starter?
Claim language“D-xylose alone”

In cultured cells, a galactosyltransferase adds galactose to the xyloside. Additional glycosyltransferases build the linkage region and extend chondroitin chains, which accumulate in the culture medium.

1.1Mechanical loading of cartilage cells

What ifWhat if cyclic compression stimulated glycosaminoglycan production in a cartilage construct?
Claim language“D-xylose alone”

Chondrocytes are embedded in an agarose hydrogel and subjected to repeated compression and release. The loading stimulates cartilage matrix production, and sulfate tracer incorporation measures the synthesis of sulfated glycosaminoglycans.

1.1Carrier-free crystalline powder

What ifWhat if a unit packet contained dry D-xylose crystals with no added carrier?
Claim language“in a physiologically acceptable medium”

Each packet contains a weighed portion of sieved D-xylose crystals. The crystals dissolve in gastrointestinal fluid after swallowing and release D-xylose for intestinal absorption.

1.1Direct supply of hyaluronan

What ifWhat if an aqueous gel supplied a preformed glycosaminoglycan to the skin surface?
Claim language“to stimulate the biosynthesis of glycosaminoglycans”

The gel contains purified sodium hyaluronate dispersed in water. The polymer forms a hydrated film on the skin and holds water at the application site.

Section 2 · machine-generated

Variations

Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.

Other field of use

Xylose exposure in reconstructed oral tissue

A laboratory tissue model uses a human oral epithelial layer grown on a porous insert. A dispensing pipette applies D-xylose in a buffered aqueous medium to the exposed surface, and matched inserts receive the medium alone. After exposure, the operator washes the inserts and collects the tissue and basal medium separately for glycosaminoglycan analysis.

Xylose exposure in veterinary tissue testing

A veterinary laboratory places canine cartilage explants in individual wells containing culture medium. The operator adds purified D-xylose in buffered medium to one group and the same volume of buffered medium to a matched control group. The laboratory collects the cartilage and surrounding medium separately and measures sulfated glycosaminoglycans in both fractions to track matrix content and release.

Component substitution

Pullulan film for oral delivery

A dissolving pullulan film replaces a compressed oral solid as the carrier for purified D-xylose. A film coater spreads an aqueous mixture of pullulan, glycerol and D-xylose onto a release liner, and a dryer removes water before a rotary die cuts the film into individual pieces. Each piece dissolves in saliva and releases D-xylose.

Parameter or scale variation

Two thicknesses for film release testing

A bench coater produces D-xylose oral films at nominal dry thicknesses of 50 and 150 micrometers using the same mixture. The operator adjusts coupon area so that both thickness groups contain the same measured mass of D-xylose per coupon. A stirred test vessel holds simulated saliva at 37 °C, and samples taken at 15, 30, 60 and 120 seconds provide release profiles expressed as a fraction of the initial D-xylose mass.

Combination with existing systems

Oral film on a pouch line

A pick-and-place station feeds cut D-xylose oral films into an existing horizontal form-fill-seal line. A camera checks that one film sits clear of the seal zone before heated jaws close the moisture-barrier pouch. An encoder links each camera result to the corresponding pouch, and a reject gate removes pouches with missing or displaced films.

Automated or data-driven variant

Automated glycosaminoglycan disaccharide profiling

A liquid handler divides samples from D-xylose-treated and vehicle-treated human cell cultures into separate aliquots for heparan sulfate and chondroitin or dermatan sulfate analysis. It adds heparinases to one aliquot and chondroitinase ABC to the other, then transfers the digests to a liquid chromatography and mass spectrometry autosampler. Software integrates disaccharide peaks against calibration curves and reports the measured amounts per unit of cellular protein.

Specific version of a part

D-xylose solution with citrate buffer

Crystalline D-xylose dissolves in purified water as the sole active ingredient. Citric acid and sodium citrate set the pH, and a concentration assay checks the filled solution.

D-xylose in an oral gel

Hydroxypropyl methylcellulose thickens purified water to form a swallowable gel. D-xylose dissolves in the aqueous phase as the sole active ingredient, and single-use packets provide a measured mass of gel.

Section 3 · quoted from USPTO records

Other work

Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.

Document AUS 2008/0027023 A1
Published
Jan 31, 2008
Filed
Jul 14, 2005
Class
A61K 31/715
Document BUS 7,732,414 B2
Published
Jun 8, 2010
Filed
Mar 13, 2006
Class
A61K 31/7008
Claim 1
Document A
Document B
1.1D-xylose alone in a physiologically acceptable medium to stimulate the biosynthesis of glycosaminoglycans, preferably at least one selected from heparan sulfate, dermatan sulfate and chondroitin sulfate.
The invention is based on a specific group of xylose-based glycosides all of which are part of the so called carbohydrate-to-protein linkage region which joins sulfated glycosaminoglycans to the core protein of their parent proteoglycans. Such glycosides can serve as primers for glycosaminoglycan synthesis.
A · US 2008/0027023 A1 · ¶ 7
Nos. 4,446,312 and 4,454,123 describe that the above-mentioned C-β-D-xylopyranoside compounds induce the biosynthesis of chondroitin sulfate while at the same time reducing the amount of proteoglycan present at the surface of the constituent cell membranes of tissues.
B · US 7,732,414 B2 · ¶ 45

An empty cell means only that no passage was reproduced there.

Statements in these documents
Although improved treatment of certain forms of cancer is now available, for many types of cancer, e.g. malignant gliomas, small cell lung cancer, tumors in the small intestine and metastatic malignant melanoma, no effective curative treatment is available.
A · US 2008/0027023 A1 · ¶ 3
With certain xyloside containing compounds the toxic effect is selective in that cancer cells are eliminated without adverse effects on normal cells.
A · US 2008/0027023 A1 · ¶ 5
This invention also relates to a cosmetic regime or regimen comprising administering to an individual in need of such treatment such a cosmetic composition.
B · US 7,732,414 B2 · ¶ 5
Cite aspatent.fyi, US 2026/0355225 A1, claim 1, first published 2026-11-19T09:44:02-05:00, https://patent.fyi/US20260355225/, SHA-256 a3f2b26bf1d2fa4de4015c10ac99c532c9707dbb2b527d7fccc37dbaa267b0b9
First published
Permanent addresshttps://patent.fyi/US20260355225/
Content fingerprint (SHA-256)a3f2b26bf1d2fa4de4015c10ac99c532c9707dbb2b527d7fccc37dbaa267b0b9
Methodv2026-11-18.2 · automated, not reviewed by a person
Correctionscorrections@patent.fyi